{
    "ticker": "HALO",
    "name": "Halozyme Therapeutics, Inc.",
    "description": "Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with unmet medical needs. Founded in 1998 and headquartered in San Diego, California, Halozyme specializes in the development of recombinant human enzymes, notably its proprietary enzyme, hyaluronidase, which enhances the absorption and distribution of biologic drugs. This technology, known as ENHANZE, is designed to improve the efficacy of therapeutic agents, particularly in oncology and other serious diseases. Halozyme's collaborations with major pharmaceutical partners, including Roche and Amgen, have enabled the development of a range of therapies that leverage its ENHANZE technology. The company is also involved in clinical trials for its own product candidates, aiming to address the needs of patients suffering from various conditions such as cancer and autoimmune disorders. Halozyme is dedicated to advancing the field of biotechnology and improving the quality of life for patients through innovative solutions and strategic partnerships. The company\u2019s commitment to research and development, alongside its focus on collaboration with industry leaders, positions it as a significant player in the biopharmaceutical landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "1998",
    "website": "https://www.halozyme.com",
    "ceo": "Helen Torley",
    "social_media": {
        "twitter": "https://twitter.com/halozyme",
        "linkedin": "https://www.linkedin.com/company/halozyme-therapeutics/"
    },
    "investor_relations": "https://investors.halozyme.com",
    "key_executives": [
        {
            "name": "Helen Torley",
            "position": "CEO"
        },
        {
            "name": "David A. Ramsay",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ENHANZE Technology",
                "Halozyme's Clinical Candidates"
            ]
        }
    ],
    "seo": {
        "meta_title": "Halozyme Therapeutics, Inc. | Biopharmaceutical Innovations",
        "meta_description": "Explore Halozyme Therapeutics, Inc., a leader in biopharmaceuticals focused on innovative therapies for unmet medical needs. Discover our ENHANZE technology and product pipeline.",
        "keywords": [
            "Halozyme",
            "Biopharmaceuticals",
            "ENHANZE",
            "Hyaluronidase",
            "Novel Therapies"
        ]
    },
    "faq": [
        {
            "question": "What is Halozyme known for?",
            "answer": "Halozyme is known for its innovative biopharmaceuticals and the ENHANZE technology that enhances drug delivery."
        },
        {
            "question": "Who is the CEO of Halozyme?",
            "answer": "Helen Torley is the CEO of Halozyme Therapeutics, Inc."
        },
        {
            "question": "Where is Halozyme headquartered?",
            "answer": "Halozyme is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Halozyme's main products?",
            "answer": "Halozyme's main product is its ENHANZE technology, along with various clinical candidates."
        },
        {
            "question": "When was Halozyme founded?",
            "answer": "Halozyme was founded in 1998."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX",
        "BMY"
    ],
    "related_stocks": [
        "GILD",
        "JNJ",
        "PFE",
        "ABBV"
    ]
}